Vedolizumab in paediatric IBD: a huge step forward but not there yet

Affiliations

¹ Paediatric Gastroenterology Department, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, Netherlands.
² Paediatric Gastroenterology Department, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, Netherlands. Electronic address: l.deridder@erasmusmc.nl.

Comment

Renz C W Klomberg et al. Lancet Gastroenterol Hepatol. 2023 Jan.

. 2023 Jan;8(1):3-5.

doi: 10.1016/S2468-1253(22)00390-9.

¹ Paediatric Gastroenterology Department, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, Netherlands.
² Paediatric Gastroenterology Department, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, Netherlands. Electronic address: l.deridder@erasmusmc.nl.

No abstract available

Conflict of interest statement

We declare no competing interests.

Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O, Shavit-Brunschwig Z, Mould DR, Stein R, Matar M, Aloi M, Ledder O, Focht G, Urlep D, Hyams J, Broide E, Weiss B, Levine J, Russell RK, Turner D. Atia O, et al. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):31-42. doi: 10.1016/S2468-1253(22)00307-7. Epub 2022 Oct 26. Lancet Gastroenterol Hepatol. 2023. PMID: 36306803